1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J, Jr.: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46(4):470-472.
2. Collaborators GBDN: Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2019, 18(5):459-480.
3. Löscher W, Potschka H, Sisodiya SM, Vezzani A: Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev 2020, 72(3):606-638.
4. Perucca P, Mula M: Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 2013, 26(3):440-449.
5. Kelley MS, Jacobs MP, Lowenstein DH: The NINDS epilepsy research benchmarks. Epilepsia 2009, 50(3):579-582.
6. Keezer MR, Sisodiya SM, Sander JW: Comorbidities of epilepsy: current concepts and future perspectives. The Lancet Neurology 2016, 15(1):106-115.
7. Gaitatzis A, Sisodiya SM, Sander JW: The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012, 53(8):1282-1293.
8. Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD: Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol 2014, 71(5):569-574.
9. Vincent A, Bien CG, Irani SR, Waters P: Autoantibodies associated with diseases of the CNS: new developments and future challenges. The Lancet Neurology 2011, 10(8):759-772.
10. Fan C, Gao Y, Liang G, Huang L, Wang J, Yang X, Shi Y, Dräger UC, Zhong M, Gao TM et al: Transcriptomics of Gabra4 knockout mice reveals common NMDAR pathways underlying autism, memory, and epilepsy. Molecular autism 2020, 11(1):13.
11. Jiang X, Lu H, Liu W, Wu Z, Wu Q, Li X, Xu Z, Hui F, Zhao Q: The overlap between Alzheimer's disease and epilepsy uncovered by transcriptome sequencing. Clinical and translational medicine 2020, 10(5):e169.
12. Xi XJ, Tang JH, Zhang BB, Xiao X, Hu XY, Wan Y, Zhou C, Lin H: Dlg4 and Vamp2 are involved in comorbid epilepsy and attention-deficit hyperactivity disorder: A microarray data study. Epilepsy Behav 2020, 110:107192.
13. Devinsky O, Schein A, Najjar S: Epilepsy associated with systemic autoimmune disorders. Epilepsy currents 2013, 13(2):62-68.
14. Guan Q: A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res 2019, 2019:7247238.
15. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE, Jr., Jones EG: Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. The Journal of neuroscience : the official journal of the Society for Neuroscience 1996, 16(1):19-30.
16. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology 2014, 15(12):550.
17. Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology 2012, 16(5):284-287.
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(43):15545-15550.
19. Benavente L, Morís G: Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol 2011, 18(1):138-143.
20. Elsehety A, Bertorini TE: Neurologic and neuropsychiatric complications of Crohn's disease. Southern medical journal 1997, 90(6):606-610.
21. Lossos A, River Y, Eliakim A, Steiner I: Neurologic aspects of inflammatory bowel disease. Neurology 1995, 45(3 Pt 1):416-421.
22. Vezzani A, Granata T: Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46(11):1724-1743.
23. Choi J, Nordli DR, Jr., Alden TD, DiPatri A, Jr., Laux L, Kelley K, Rosenow J, Schuele SU, Rajaram V, Koh S: Cellular injury and neuroinflammation in children with chronic intractable epilepsy. Journal of neuroinflammation 2009, 6:38.
24. Ho YH, Lin YT, Wu CW, Chao YM, Chang AY, Chan JY: Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus. Journal of biomedical science 2015, 22(1):46.
25. Lin Z, Si Q, Xiaoyi Z: Association between epilepsy and systemic autoimmune diseases: A meta-analysis. Seizure 2016, 41:160-166.
26. Uddin J, Garcia HH, Gilman RH, Gonzalez AE, Friedland JS: Monocyte-astrocyte networks and the regulation of chemokine secretion in neurocysticercosis. J Immunol 2005, 175(5):3273-3281.
27. Baggiolini M, Clark-Lewis I: Interleukin-8, a chemotactic and inflammatory cytokine. FEBS letters 1992, 307(1):97-101.
28. Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H: CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother 2021, 138:111427.
29. Mazdeh M, Omrani MD, Sayad A, Komaki A, Arsang-Jang S, Taheri M, Ghafouri-Fard S: Expression analysis of cytokine coding genes in epileptic patients. Cytokine 2018, 110:284-287.
30. de Vries EE, van den Munckhof B, Braun KP, van Royen-Kerkhof A, de Jager W, Jansen FE: Inflammatory mediators in human epilepsy: A systematic review and meta-analysis. Neurosci Biobehav Rev 2016, 63:177-190.
31. Farias-Moeller R, LaFrance-Corey R, Bartolini L, Wells EM, Baker M, Doslea A, Suslovic W, Greenberg J, Carpenter JL, Howe CL: Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. Epilepsia 2018, 59(9):1753-1763.
32. Tham TN, Lazarini F, Franceschini IA, Lachapelle F, Amara A, Dubois-Dalcq M: Developmental pattern of expression of the alpha chemokine stromal cell-derived factor 1 in the rat central nervous system. The European journal of neuroscience 2001, 13(5):845-856.
33. Tissir F, Wang CE, Goffinet AM: Expression of the chemokine receptor Cxcr4 mRNA during mouse brain development. Brain research Developmental brain research 2004, 149(1):63-71.
34. McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J: Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Developmental biology 1999, 213(2):442-456.
35. Lin X, Wang H, Li Y, Yang J, Yang R, Wei D, Zhang J, Yang D, Wang B, Ren X et al: Functional characterization of CXCR4 in mediating the expression of protein C system in experimental ulcerative colitis. American journal of translational research 2017, 9(11):4821-4835.
36. Hosomi S, Oshitani N, Kamata N, Sogawa M, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Tominaga K, Watanabe T et al: Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clinical and experimental immunology 2011, 163(2):215-224.
37. Zhang X, Liu T, Zhou Z, Mu X, Song C, Xiao T, Zhao M, Zhao C: Enriched Environment Altered Aberrant Hippocampal Neurogenesis and Improved Long-Term Consequences After Temporal Lobe Epilepsy in Adult Rats. J Mol Neurosci 2015, 56(2):409-421.
38. Song C, Xu W, Zhang X, Wang S, Zhu G, Xiao T, Zhao M, Zhao C: CXCR4 Antagonist AMD3100 Suppresses the Long-Term Abnormal Structural Changes of Newborn Neurons in the Intraventricular Kainic Acid Model of Epilepsy. Mol Neurobiol 2016, 53(3):1518-1532.
39. Zhou Z, Liu T, Sun X, Mu X, Zhu G, Xiao T, Zhao M, Zhao C: CXCR4 antagonist AMD3100 reverses the neurogenesis promoted by enriched environment and suppresses long-term seizure activity in adult rats of temporal lobe epilepsy. Behav Brain Res 2017, 322(Pt A):83-91.
40. Li X, Lan X, Zhao Y, Wang G, Shi G, Li H, Hu Y, Xu X, Zhang B, Ye K et al: SDF-1/CXCR4 axis enhances the immunomodulation of human endometrial regenerative cells in alleviating experimental colitis. Stem Cell Res Ther 2019, 10(1):204.
41. Xia XM, Wang FY, Xu WA, Wang ZK, Liu J, Lu YK, Jin XX, Lu H, Shen YZ: CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World J Gastroenterol 2010, 16(23):2873-2880.
42. Xia XM, Wang FY, Zhou J, Hu KF, Li SW, Zou BB: CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PLoS One 2011, 6(11):e27282.
43. Mikami S, Nakase H, Yamamoto S, Takeda Y, Yoshino T, Kasahara K, Ueno S, Uza N, Oishi S, Fujii N et al: Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. The Journal of pharmacology and experimental therapeutics 2008, 327(2):383-392.
44. Li XW, Yang F, Wang YG, Wang JC, Ma L, Jiang W: Brain recruitment of dendritic cells following Li-pilocarpine induced status epilepticus in adult rats. Brain Res Bull 2013, 91:8-13.